Tom 13, Nr 1 (2018)
CHOROBY STRUKTURALNE SERCA
Opublikowany online: 2018-04-10
Wyświetlenia strony
6148
Wyświetlenia/pobrania artykułu
8554
Komu i dlaczego zamykać uszko lewego przedsionka w 2018 roku?
Kardiol Inwazyjna 2018;13(1):28-32.
Streszczenie
Doustna terapia przeciwzakrzepowa zmniejsza ryzyko udaru mózgu u pacjentów z migotaniem przedsionków. Jednak pomimo obecności wskazań do takiej terapii nie jest ona stosowana u ponad 1/3 chorych z migotaniem przedsionków, głównie z uwagi na związane z nią zwiększone ryzyko powikłań krwotocznych lub nietolerancję takiego leczenia. Zabieg zamknięcia uszka lewego przedsionka (LAAO) ma celu zmniejszenie ryzyka udaru mózgu poprzez eliminacje potencjalnego źródła zatorowości. W Polsce zabieg LAAO jest przeznaczony przede wszystkim dla chorych z niezastawkowym migotaniem przedsionków, czynnikami ryzyka udaru mózgu (CHA2DS2VASc co najmniej 2) oraz przeciwwskazaniami do przewlekłej doustnej antykoagulacji.
Słowa kluczowe: zamknięcie uszka lewego przedsionkaleczenie przeciwzakrzepowe
Referencje
- Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014; 129(8): 837–847.
- Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009; 104(11): 1534–1539.
- Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996; 27(10): 1760–1764.
- Tu HTH, Campbell BCV, Christensen S, et al. Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) Investigators. Pathophysiological determinants of worse stroke outcome in atrial fibrillation. Cerebrovasc Dis. 2010; 30(4): 389–395.
- Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12): 857–867.
- Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383(9921): 955–962.
- Steinberg BA, Greiner MA, Hammill BG, et al. Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation. Cardiovasc Ther. 2015; 33(4): 177–183.
- O'Brien EC, Holmes DN, Ansell JE, et al. Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J. 2014; 167(4): 601–609.e1.
- Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014; 16(1): 6–14.
- Lip GYH, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace. 2014; 16(3): 308–319.
- Beyer-Westendorf J, Ehlken B, Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace. 2016; 18(8): 1150–1157.
- Onalan O, Crystal E. Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation. Stroke. 2007; 38(2 Suppl): 624–630.
- Handke M, Harloff A, Hetzel A, et al. Left atrial appendage flow velocity as a quantitative surrogate parameter for thromboembolic risk: determinants and relationship to spontaneous echocontrast and thrombus formation--a transesophageal echocardiographic study in 500 patients with cerebral ischemia. J Am Soc Echocardiogr. 2005; 18(12): 1366–1372.
- Sahin T, Ural D, Kilic T, et al. Evaluation of left atrial appendage functions according to different etiologies of atrial fibrillation with a tissue Doppler imaging technique by using transesophageal echocardiography. Echocardiography. 2009; 26(2): 171–181.
- Tamura H, Watanabe T, Nishiyama S, et al. Prognostic value of low left atrial appendage wall velocity in patients with ischemic stroke and atrial fibrillation. J Am Soc Echocardiogr. 2012; 25(5): 576–583.
- Di Biase L, Santangeli P, Anselmino M, et al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol. 2012; 60(6): 531–538.
- Kirchhof P, Benussi S, Kotecha D, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38): 2893–2962.
- Kirchhof P, Benussi S, Kotecha D, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38): 2893–2962.
- Grygier M, Wojakowski W, Smolka G, et al. Przezcewnikowe zamykanie uszka lewego przedsionka -stanowisko grupy ekspertów powołanej przez Asocjację Interwencji Sercowo-Naczyniowych oraz Sekcję Rytmu Serca Polskiego Towarzystwa Kardiologicznego. Kardiologia Polska. 2014.
- Santoro G, Meucci F, Stolcova M, et al. Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug. EuroIntervention. 2016; 11(10): 1188–1194.
- Boersma LVA, Schmidt B, Betts TR, et al. EWOLUTION investigators. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J. 2016; 37(31): 2465–2474.
- Reddy VY, Möbius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol. 2013; 61(25): 2551–2556.
- Holmes DR, Reddy VY, Turi ZG, et al. PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009; 374(9689): 534–542.
- Reddy VY, Sievert H, Halperin J, et al. PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014; 312(19): 1988–1998.
- Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation. 2011; 123(4): 417–424.
- Holmes DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014; 64(1): 1–12.
- Reddy VY, Akehurst RL, Armstrong SO, et al. Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF: Warfarin Versus NOACs Versus LAA Closure. J Am Coll Cardiol. 2015; 66(24): 2728–2739.
